CD274 and neoplasm: As supported, anti-4-1BB mAb combined with anti-PD-L1 mAb significantly increased the capacity of CD8+CD103+ T cells to kill tumor cells rather than CD8+CD103− T cells, which signified that PD-1 and 4-1BB can deliver selective costimulatory signals to CD103+CD8+ T cells.